Topical rharmacol ogk al Agenu
A mitri ptyline and Ga bapenrtn arc well known syste mic drugs used in the ma nagem em of neuropathic pain. H owCVCl, they are also used as topical agents , appare m ly with some success, pa rticularly the use o f gabape m in in vulvo dy nia. Th e mechan isms for ropkal rel ief o f pain seem ro differ from their ce ntral e ffect s, and the mechani sm ofaction is u nknown. l he uses of many agents are limited ro sym parherically medi ated pai n ' a nd rrear men r-restsranr pa in. as they are nOI freely available, although the re a re ongoing st udies lo okin g im o the use o f var ious com binatio ns of d ifferen t agem s to pically, Amir rip tyline crea m has been used in th e managem em o f posrrrau manc neuropath ic pain t, but in srud jes when compa red with 5% lidocaine crea m' and 3.3% d oxepin cream", arn irrip rylin e cream was fo u nd to be less efficacious. H owever, wh en co mbi ned with keram ine cream , topical a mitriptyli ne showed promising results in ne uro pathic pain Slates' a nd a lso in th e ma nagemen t o f refracto ry proctodyn ia".
Th e use of th e above com bin ed with Baclofen in a crea m fo rm has bee n show n to be e ffective in chc morhe rapy-Induced perip he ral neurop athy", Topical G abapem in has bee n used in {he man agem em o f localised a nd general ised vulvod ynia'" a nd anecd otall y has been tri ed in ot her neuropathic pain stares. Lidoca ine cream s and EM.LA are also used . especially for mu cous mem branes, but has largely been replaced by 5% lidoca ine plasters o n skin , wh ich is di scussed below.
Keramln e is used as a systemic agent in the manageme nt o f neu ropath ic pain , bu t its use as a topical gel has also been explo red ".
It has been used in the manage me nt ofo ral mucositis'! and its usc in com bina tion with amitriptyli ne c ream has bee n di scussed befo re' ..", Clonldtne is a nothe r agent that has been tried topic ally" and it works by blo cking the e mergi ng pain slgnals at pe rip he ral te rm ina ls via alp ha -2 ad renocepr o rs witho ut p roducing undesirabl e cent ral side effects!'. GTN spray was also tried with some success in the ma nagement of pa in ful diabetic neuropathy either as a sole agent o r in co mbination with an ticonvulsanrs'".
Th e agent th at is com mo nly used for localised neuro pat h ic pains includin g painful d iabe tic neuro pathy and post-herpeti c neura lgia is capsaicin"-", [I is usually used as 3 0 .0 25% or 0.0 7 5% crea m and is licen sed foe rhe manage me nt of painful diabetic ne u ro path y"!", Co mb ination of doxepin and capsaicin crea m was fou nd to produce fast er results in another stud y' ". Some p. mcnts find it di fficulr 10 be com plian t with {he treat men t d ue to the bu rn ing na ture o f th e crea m and it need s ro be app lied 3-4 tim es a day fo r several weeks before p roducing pa in relief. Th e 8% capsa icin pat ch, which is a Sing le applicati on could imp rove o n thi s a nd is di scussed in d etail below.
5% Lidocaine Plaster
Top ical 5% lidocain e plaste r has been aroun d since late 1999 and is a rc pical a nalgesic, wh ich is recommended by some algor ith ms :1\ first line the rapy for the rrean ncn r of localised , peri phe ral neuropath ic pai n1',u. Each 10 em x 14 e rn plaster co nta ins 700 mg (5% w/ w) lidocaine in a wh ite h ydrogel plaster co ntaining adh esive material and is applie-d for a period no 101lger than 12 ho urs with a su bseq ue nt plaster-free interval for a not he r 12 hou rs H ; a ma ximum of th ree plasters a rc used at a rtme". The application o f th e plaster over th e inta ct skin o f th e affected area is usually well-tol erat ed and applicati on site side effects like erythem a, rash and pruritus are mostly self-lim iting' i. Patie nt s need to be followed up after 2-4 weeks and if th ere is no analgesic benefit in th at period , it is un likely to gel more benefit tha n the bar rier effecl.
Th e rnechanisrno f action is srill u nclear, bur the lo cal an algesic effecl is by stabilising neu ronal m em bran es, and from a nimalstudies it is tho ugh t to do wn -regulate the sod iu m cha n nels p resent in th e pe rip her al ne rve e ndi ngs , reducing ecto pic nocicepti ve pa in signal transmis sion ". As a long -te rm conse q uence , reduction of peripheral nerve input may co u nter act cen tral sensitisatio n. lidocai ne ind uces a TRPVI dependent release o fCG RI' , wh ich is a key compon ent of neu rogeni c inflamm ation a nd lon g-term topical ap plicatio n of hdo catne reduces nerve fibre dens lry in the ep i derm is~O\J'; this deg encmno n may explain the observed loss of pain" . Add ilion ally, the plaster act s as a barrier protecting the skin from mechanical stimuli, wh ich can n igger pain sensations d ue 10 allodynia and hyperpathia.
The current licensed indication for 5% lidocaine plaster is for POStherpetic neuralgia". Various stud ies evaluati ng the long-term efficacy, safety and tolerability of the lidocaine plaster show consistent and sustained lon g-term pain relief for up to 24 months and long er ' . The data furth er confirms that in newly diagnosed pati ent s, pain relief was achieved at 1 week of treatment and subsequent reductio ns occurred in the weeks thereafter. 5% lidocaine plasters have also been successfully used in patient s with other [}'pt.'S of neu ropathi c pain states, eit her as a single agenr' "or in co mbinatio n ". Prom ising results have also been obtained with the use of5% lidocaine patch fur the treatm ent of r nild-ro-modcrare carpal tunn el syndrome, the efficacy being comparable to rhar of the more invasive anaesrheric/ corticosteroid injectio n otherwise used " . II was found that the plaster was well rolerared by the patients who also repo n ed a low side effect profile.
5% lidocaine plasters are also used in treating other pain co nditions includi ng myofascial pain syndrome (M PS), caused by trigger points in muscle o r muscle fascia. l he existing standard treatment fur this is infiltration of the trigger points wirh local anaestheti c . 1ste roids: however this interven tion nor mally can produ ce some discomfort in the patients. the application of top ical 5% lidocaine plasters fur the sympro rns of MrS was found to be effixtive and highly acceptable 10 pati ent s with MrS" . The me of5% lidocaine plasters in three d iflC rent ch ronic pain conditions fur tWO weeks also had a significant reduction and impact on all pain measures assessed by neuropathic pain scoring " . It has also been shown that 5% lidocaine plaster can be used as an additional rhcrapeudc option in ch ronic back pain " and also showed no statist ically significant difference between using the 5% lidocaine plaster versus COX-2 inhibi tors in treatin g osteoarthritis pain " .
In summary, 5% lidocaine plaster is an effective means of treatin g ongo ing pain and allodynla d ue to localised neuropathic pain and diverse peripheral neuropathies. The sustained efficacy, co mbined with us safety and tolerability profile results in a favourable ben efitrisk ratio, suggesting its safery for long-term use. Ho wever, it is 10 be noted that, being licensed for post-herpetic neuralgia, rhe predominant use is st ill in neuropathic pain and not for musculoskeletal paln .
8% Ca psaicin Parch
Ca psaicin (8-methy-N-v;lIIi1l yl.6-nonenamidel is the active component of the chilli pepper and is an agon ist of the transient receptor potential vanilloid-I receptor (T RPVI) " . Topical capsaicin creams, 0 .025% and 0.075% , have been used over twent y years in the manag emenl of peripheral neu ropathic pain s" , bur tend to have limited analgesic effect, as it needs to be applied up 10 four tim es daily for several weeks, which could lead ru red uced compliance rares. Some patients also com plain ofexperiencing a burning sensation when using the cream" , The low dose topical capsaicin cream rna)" red uce neuropathic pain in PH N but in one trial it failed show efficacy in H IV-aS5OCiatcd distal sensory polyneuro parhy'".
A high concentration capsaicin (8%w/w) parch was approved in the UK in 20 10 for the rrcarrnem of PHN and other periph eral neuropathic states other than dubenc neuropathy. Each 14 ern x 20 cm parch , with a rom! of 179 mg of capsaicin (640 mcglcm2l in the silicone-adhesive mixture, ls designed to deliver a therapeutic dose of capsaicin d uring a single application of 30-60 minutes. Capsaicin causes an initial enhanced stimulation ofTRPV1-exprCS5ing cutaneous noctceprors that may he associated with painful sensations, followed by 01 reduction in the TRPV1-expressing nocicept ors. leadin g to prolonged analgesia" . Over a period of mo nths, rhere may be a grad ual re-emergence of the neu ropath }'d ue 10 nerve fibre reinncrvat km of the n eared area. The mechani sm of action is thought to be selective and reversible defun ctioning of cutaneous sensory nerve endings expressing T RPV I . However, large myelinated nerve fibres are unaffected , thereb y preserving the integrity of prcr ective touch, vibratory and thermal connections". This is important as it means capsaicin treatm ent can lead to redu ction in pain witho ut clinically relevant changes in prot ective sensation.
Evidence from several co ntrolled clinical rrials have dcmons rrarcd thar applying a single 60 minute high concemranon capsaicin patch can signific";\Jlrlr reduce neuropathic pain in padems with PH N' J.< '. The stud ies also co nfirmed that it could be effective as a mo nor herapy or in conjunction with othe r pain analgesia" "' ''' '' and mo re importantly, the pain relief was ma inrntncd for up 10 at least 12 weeks' ..... The patch showed greate r lmprovemen r in mean pain scores at all assessment nmes "-". A raudo mtsed do uble blind con trolled study in patient s with PH N fur at lca sr thr ee months showed that following treatment with the 8% capsaicin patch, pain scores began declining as early as the end of dar 1 and were on average n. .JIICed by 36% during the firSI week'''·' .
Studies have also shown that the 8% capsaicin patch is effective in Ht v -assoclared distal sensory polyneuro pathr, a painful condition with limit ed effective treatmem s....'..·... A mulrtcenulc doubl e blind co nt rolled dose-finding study, which evaluated the safety and efficacy of the 8% patch hut studied with different durations of applicat ion -30, 60 or 90 minutes in treating I'HN" . In summary the authors found thar a single top ical app lication of the patch provided pain reductio n for up 10 3 mon ths" . Treatment dura lion of 60 minut es was found to be the lowest effective dose tim e and generally well tolerated, but for the treatment of painful HI V neurop ath y of the feet, it was found that a 30 minutes ap plication gave similar analgesic effect for a similar duearlon"-", Side effects of8% capsaicin are pred ominantly localised, such as applicarkm site pain, pruritus and papules: these responded to localised coo ling and analgesics, and lasted only fur a few days4' ... ,. A tran sient , but clin ically insignificant rise in blood pressure has also been noted during the duration of the patch application and was self-limit ing" . Exposure ro capsaicin may resuh in nasopharyngilis a nd th is can be avoid ed by careful remova l, rollin g the patch inwards to avo id co ntact, for safe d isposa l.
In summary, hi gh dos e capsaicin patch is generally well role rared by parienr s and appea rs to have some po tent ial advan tages over some of th e curre nt first line agem s in term of side effixl profile. Poo r co m pliance from padems for capsaicin cream is avoided, as the whole thera peut ic dose is del ivered during a single supervised ap plicati on . PENS gives good analgesic results in patient s with pos t-irradiation allod ynia and following tr igemi nal field neuro pathy followin g head and neck ca ncer surgery a nd radlorherapy'". These patient s reported imp roved q uality of hfe and co uld make a signifiu nt reduction in o plo ld analgesia and also system ic neuro pathic pain agent s'", PENS therap y is co nt raindica ted in th e presen<::e of dema nd type card iac pacemakers and patie nt refusal. Ca uno n is to be exercised in patient s kn own ro have heart disease, epilepsy, o n ant icoagula nts and in pregnancy. PENS th erap y is best deferred when th ere is local o r systemic mfecno n or coagulo parhy, Possible adverse events may inclu de temp ora ry flare of pain, bleedi ng or haemaroma ar pro be insertio n site, and th e possibility of in fectio n at the probe e ntr y po int ; rnisplace rne nr of the probe may cause tem po rary neuro praxia. thou gh this is very rare.
PENS can be used as a d iagnostic th erap y to ident ifY patients who are likely to bene fit from a perm anentl y fmpla med neurostimula ror and co uld reduc e the incid enc e of pa tients who fail 10 be nefit fron l a lengthy, pot enti ally t rau matic an d costly proced urecl . D istin guishin g patients who may sta nd to benefit fro m permane ntly implantable ncurosrlmula rion devices, from th ose who may not , and the abilit y to reco gnise th ose who will gain an en hanced qu ality ot llfe thro ugh o ngotng PENS therapy, offers clear clini cal and economic advantages when consi dered ill co n junctio n with o the r ncuro srlmularion therapies. It has also been used with suc cess in patients w ith focal neu ropat hic pain in pa tient s with cancer who req ui re freq uent MRI scans which make an implant able ncur osnmularor conrraindica rcd'" , sysrems" have also k en described in ani mal stu d ies. There may also be an am i-nociceptive efft'C1 produced simply due to radtofrequeucy appli cation ' }.
The use of rad tofrequency lesioning for trigeminal neuralgia has been in practice for nearly foil}' years' '; th e techniq ue is well described " and studies have show n that con vent ion al radtofrequency is far more effective in sustain ing analge sia than pul sed leslonlng", Percutaneous radlofrequency rhizoto my has been effective in id iopathic trigem inal neu ralgia, symptomat ic facial pain and herp es zoster of th e fifth cranial nerve, but not effecdve in atypical facial paln" . It has been the reco mm ended o ption for treatin g tr igeminal pain in th e elderly. bur microvascula r decompression remai ns th e firsrline cho ice fur youn ger partenrs" . The procedure is nOI without compli cations and apan from pain and bru ising, m ajor complicatio ns such as other cra nial nerve palsies" . subarachnoid haemmorhage" and rhtnonheoa" have also been reported. Targeting th e sphenopalatine ganglion "' , particularly usin g ad vanced imaging induding CTguidance" and virt ual reality techn iques" has high er efficacy and reduced risk of co mplicat ions. Radiofrequ ency neurolysis of th e in fra-orbital ner....e has been do ne when trigem inal gangli on o r posterio r roo t ablu non is co ntraind icated" . Pulsed radiofreq ue ncy has been used in th e treatmen t of occipital neural gia with th e pain impro....ing substant ially in mo re tha n half the number of palie ms"",8'.
Sevcral other neuropathic pain co nditi o ns havc been n eared with radiofrequ ency with good to exceptional results as reponed in case series, Pulsed radiofrequ elKY of the lateral cutaneous nerve of th e thigh has been used in successfully treatin g m eralgia pam esrhcrtca " , It has also been used with success in managing groin pain and o rch ialgia'" and also refracto ry pudendal neuralgia'"', 'Ihcre are case repons of effective radlo freq uency lesioning for o bruraro r nerve ne uropathy" for co nditions such as hip arthritis. Th e effecrs of producing a radiofrcqucncy lesion ad jacent to the dorsal root ganglion in parle nrs with th oracic segmental pain has also been reported . with 67% of patient s repo ning pain relief at 8 weeks and half ehe patients ba....in g relief at 36 w(. 'Cks· l , More recently it has been shown th at pu lsed radtofr equency of the do rsal roo t ganglio n is superior to pha rmaco th erapy Ot pulsed mdjofr equen cy of the lnrcr cosral nerves in th e rrearmem of chro nic postsurgical th oracic pain' ". Th ere are also case repo rtS of a-guided dorsal roo t ganglion thermoc oagulatio n for treating post herpeti c neural gia, whe re the majo rity of patients had excellent pain relief and oth ers had a decrease in syr nproms" . Radiofrequen cy lesioni ng of th e th oracic paravertebral nerve fo r refracto ry neuropathic pain following breast cancer .lurger}" has also been repo rted", There are several case repo rts and case series regard ing th e use of radiofrequ ency ablanon in th e mana gement of lower limb phauro r n pain, incl udin g pu lsed radiofrequency of the sciatic nerve'", The patients repor ted impro ved pro sthet ic to lerance and reducti on of oral analgesic medicarions. The analgesic effect is th ough t to be d ue 10 inh ibit io n of evoked synaptic activiI Y" . It has also been reponed rhar there could be increased pain, new pain syndro mes and also abno rmal sweating in the limb srur np'" . Pulsed radiofrequency has also been used in treating myo fasclal n igger points and scar neurom as with 67% of rhe pati ent s reporti ng pain relief lasting between 6 to 12 weeks" , It has also been used in treatin g patients w ith chronic neuropathic spinal pain after failed conservative man agement'?', A 12-yC3 r lon g-term retros pective analysis of using radiofrequency appli cation to areas of pa in in th e treat ment of neu roge nic heel pain has show n a high success rate with few associated risks and less po st-ope rative mor bidity'?'. Radlofrequ ency a blation has been usedwith success for th e mana gem ent of prolonged mod erat e to severe heel pain associated with plantar f. 'lSCi itis'O l, Cervico-rho racic or lumbar sympathectomy fo r neuro pathic pa in an d com plex regional pain synd ro me (C RPS) has poor evide nce in lite rature du e to lack of large well-designed srudfcs''". However, radlcfreq uency lesio ns of th e ste llate ganglion have been used with success in C RrS Type 2, ischaemic pain, cervtcobrachlalgla an d post-t hor acoto my painI'". Pulsed radlcfreq ucncy lu mb ar sym parholysis has also been used in the management of C RI'S in a parien r with spinal inj ury "" . H owever, th e e....id cnce base fo r th e use of radiofrequency abla tio n fur rhese condit ions has not yet been valid ated by ran do miscd controlled trials'''' .
Summary
Topical agent s such as 5% Lidocaine plasters, 8% Capsaicin patch and pr ocedu res [such as PEN S The rapy give th e added opnon of delivering pain relief locally whhoue th e slde-eflccts of system ic drugs fo r localised neuropath ic pain. Thou gh radlofrequcncy techniques are widely used and there is mod erat e evide nce fo r face'! joint neurotom y, more well-designed studies need to be cond ucted 10 gather more evidence in its use in o rher neuropathic pa in states,
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